Core Viewpoint - Exelixis, Inc. is highlighted as a promising healthcare stock under $50, with a recent price target revision by Barclays indicating a positive outlook for the company [1]. Group 1: Financial Updates - Barclays revised the price target for Exelixis, Inc. to $44 from $41 while maintaining an Equal Weight rating [1]. Group 2: Drug Development - Exelixis announced the acceptance of its New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for treating adult patients with metastatic colorectal cancer [2]. - The FDA has assigned a standard review for zanzalintinib, with a target action date of December 3, 2026 [3]. - Dana T. Aftab, Ph.D., emphasized the potential of zanzalintinib to provide a novel mechanism of action for previously treated metastatic colorectal cancer patients if approved [3]. Group 3: Company Overview - Exelixis, Inc. focuses on discovering, developing, and commercializing new medicines for difficult-to-treat cancers, with a product portfolio that includes cabometyx, cometriq, and cotellic [4].

ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Exousia Pro, Inc. (OTCID: MAJI), a clinical-stage biotechnology company specializing in proprietary exosome-based delivery systems, is pleased to announce a significant acceleration in its healthcare vertical with the execution of a third Letter of Intent (LOI) to acquire an established telehealth organization. Strategic Infrastructure & Direct-to-Patient Network This third acquisition represents a cornerstone in Exousia’s strategy to build a vertically integ ...

HOUSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chairman and CEO Pete O’Heeron has been invited to serve as a main stage speaker at the upcoming A4LI’s H-SPAN Summit at Georgetown University. The summit, ta ...

STOCKHOLM, Sweden, 10 February 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer to lead the transition of the company’s lead vaccine candidate SVF-001 to phase 1 clinical development. SVF Vaccines develops DNA vaccines and immunotherapies based on proprietary technology originating from Karolinska Institutet. Ahead of entering first-in-human phase 1 clinical development with its lead vaccine candidate SVF-0 ...

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. Cambridge, UK, 10 February 2026 – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that Dr Amy Walker has been appointed as ...

The Company signed a non-binding MOU agreement with Arrow Aviation, a lucrative high- growth company with annual unaudited revenues of approximately $19 million and approximately $3 million adjusted EBITDA Raanana, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, recently announced the signing of a non-binding Memorandum of Understanding (MOU) with Arrow Aviation Ltd. ...

Moderna, Inc. (NASDAQ:MRNA) is one of the best healthcare stocks under $50 to invest in. Morgan Stanley reiterated a Hold rating on Moderna, Inc. (NASDAQ:MRNA) on February 2, setting a price target of $28.00. In a separate development, Moderna, Inc. (NASDAQ:MRNA) announced on January 29 a strategic collaboration with Recordati for the advancement of the former’s investigational propionic acidemia therapeutic, mRNA-3927, through the final stages of clinical development and global commercialization upon appr ...

Core Insights - Defence Therapeutics Inc. is advancing its Accum® platform for antibody-drug conjugate (ADC) applications, as discussed in a recent Scientific Advisory Board meeting [1][2]. Group 1: Scientific Advisory Board Meeting - The meeting on January 30, 2026, focused on enhancing the strategic positioning of Accum® for ADC applications, bringing together experts in ADC chemistry, experimental design, and value creation [1][2]. - The discussion aimed to identify critical scientific questions, refine development priorities, and align data generation with the expectations of future clinical and pharmaceutical partners [2]. Group 2: Expert Contributions - Contributions from experts such as Rob Leanna, Danny Chui, and Brendan Hussey provided insights into ADC development, drug-linker chemistry, and clinical advancement, guiding the next phase of Accum® development [3]. - The multidisciplinary dialogue is expected to refine the Accum® ADC development roadmap, aligning platform capabilities with clinical development requirements and partnering considerations [4]. Group 3: Company Overview - Defence Therapeutics is committed to enhancing cancer treatment efficacy and safety through its Accum® precision drug delivery platform, aiming to improve the potency of ADCs and reduce side effects [5]. - The company seeks to collaborate with pharmaceutical and biotech partners to bring transformative therapies to patients [5].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Stock Market Today: Dow Falls As Jobs Report Looms; AI Stock Monday Plunges | Investor's Business DailyBREAKING: [Hims & Hers Halts Wegovy Knockoff]---Futures for the Dow Jones Industrial Average and other major stock indexes moved lower Monday, as Wall Street awaited this week's rescheduled January jobs report. An early loser on the stock market today was artificial intelligence stock Monday.com (MNDY), which reported a disappointing full-year outlook. On Monday, Dow Jones futures lost 0.2%, as did S&P 500 ...